KRAS and non-small cell lung carcinoma: When looking across several meta-analyses that contained large phase III randomized studies (Checkmate-57, POPLAR, and OAK) on pre-treated patients, there was a clear predictive benefit with ICI vs. chemotherapy with regard to OS and patients with KRAS-mutated NSCLC (HR.